ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1869

“Rheum to Diagnosis”: Uncovering Impediments to Accurate Diagnosis of Non-radiographic Axial Spondylarthritis (nr-axSpA)

Sonam Kiwalkar1, Atul Deodhar1 and Richard Howard2, 1Oregon Health & Science University, Portland, OR, 2Spondylitis Association of America, Van Nuys, CA

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Back pain, Inflammation, Qualitative Research, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: In the US, there is up to a 14-year delay in axSpA diagnosis, which is likely greater for nr-axSpA.1 Impediments to timely diagnosis of nr-axSpA are unknown. This two-phased study used a grounded theory analytical approach to understand the healthcare journey leading to nr-axSpA diagnosis and factors contributing to diagnostic delay.

Methods: Adults with nr-axSpA fulfilling the eligibility criteria of rheumatologist-confirmed diagnosis of nr-axSpA, chronic back pain for ≥3 months starting before age 45, and presence of characteristic SpA symptoms were recruited from February-May 2020 via the Spondylitis Association of America newsletter, social media channels, and from back pain patient databases. In the qualitative component of the study, semi-structured telephone interviews with 25 patients and 15 rheumatologists were conducted to identify barriers and overarching themes. For the quantitative component, patients completed a detailed online questionnaire.

Results: Quantitative analysis was conducted on 125 patients (mean age, 43.5 years [range: 18-73 years]; female 74%; white 84%, LatinX 3%, and black 2%; bachelor’s or advanced degree in 72%). Half of patients had seen ≥4 different healthcare providers (HCPs) before seeing a rheumatologist (Figure 1) and 50% saw ≥2 rheumatologists before receiving the nr-axSpA diagnosis. The interval from symptom onset to nr-axSpA diagnosis ranged between ≤2 years in 40% to ≥11 years in 25% (Figure 2). Both qualitative interviews and quantitative survey responses found that patients often perceived their symptoms as a typical consequence of activity or their age (Table 1). When patients did seek medical care, clinicians frequently minimized, overlooked, or misinterpreted signs and symptoms of inflammatory disease, particularly in young and female patients.  Survey participants perceived these issues as leading barriers to timely diagnosis.

Conclusion: Patients with nr-axSpA often see multiple HCPs before arriving at the diagnosis. While rheumatologists play a critical role in diagnosis, disease recognition by clinicians in other specialties is key for early referral. Findings suggest that both patients and clinicians may be unfamiliar with inflammatory back pain, and nr-axSpA—particularly in young, or female patients, or in those with normal x-rays. Education on the cardinal features, epidemiology, burden, and benefits of timely diagnosis of nr-axSpA is warranted for providers who commonly manage back pain.

  1. Deodhar A, et al. Arthritis Rheum 2016;68:1669-1676.

Figure 1. Health Encounters Leading to nr-axSpA Diagnosis

Figure 2. Duration of nr-axSpA Symptoms Before Diagnosis Established (N = 125)

Table 1. Barriers to nr-axSpA Diagnosis – Comparison of Qualitative and Quantitative Findings


Disclosure: S. Kiwalkar, None; A. Deodhar, AbbVie, 2, 5, Eli Lilly, 2, 5, GlaxoSmithKline, 2, 5, Novartis, 2, 5, Janssen, 5, Pfizer, 2, 5, Boehringer Ingelheim, 5, UCB Pharma, 2, 5, Amgen Inc., 5, Celgene, 5, Galapagos, 5, Bristol-Myers Squibb, 2; R. Howard, Novartis, 1, 5, AbbVie, 1, Amgen, 1, Bristol-Myers Squibb, 1, GSK, 1, Johnson & Johnson, 1, Lilly, 1, Merck, 1, Pfizer, 1, Teva, 1.

To cite this abstract in AMA style:

Kiwalkar S, Deodhar A, Howard R. “Rheum to Diagnosis”: Uncovering Impediments to Accurate Diagnosis of Non-radiographic Axial Spondylarthritis (nr-axSpA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/rheum-to-diagnosis-uncovering-impediments-to-accurate-diagnosis-of-non-radiographic-axial-spondylarthritis-nr-axspa/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheum-to-diagnosis-uncovering-impediments-to-accurate-diagnosis-of-non-radiographic-axial-spondylarthritis-nr-axspa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology